{"entity":{"id":"nct05541822","kind":"trial","name":"To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation","aka":[],"tldr":"A phase 2 trial of Lazertinib in advanced solid tumours, run by Abion Inc, now recruiting.","summary":"To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation is a phase 2 interventional study registered as NCT05541822 by Abion Inc, with 178 participants planned, started 2023-01-17 and due to reach its primary completion in 2029-02. Interventions recorded: Vabametkib and Lazertinib.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05541822","url":"https://clinicaltrials.gov/study/NCT05541822"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["lazertinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05541822","phase":"2","setting":"A Phase 2 Multicenter, Open-Label, Parallel Cohort Expansion Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-Mesenchymal-epithelial Transition Factor (c-MET) Dysregulation","sponsor":"Abion Inc","participation":[{"nct":"NCT05541822","source":"https://clinicaltrials.gov/study/NCT05541822","fetchedAt":"2026-10-07T16:53:45.224Z","studySha256":"fe11f1905ef62963204afa1333a290d7504e36d1fa840eec50b1a63b49b9431e","overallStatus":"RECRUITING","lastUpdatePosted":"2025-05-22","leadSponsor":"Abion Inc","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":178,"enrolmentType":"ESTIMATED","siteCount":24,"recruitingSiteCount":23,"countries":["South Korea","Taiwan","United States"]}],"started":"2023-01-17","startedType":"actual","enrolled":178,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05541822/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"lazertinib","kind":"drug","name":"Lazertinib","route":"/drugs/lazertinib/"}]}}